M
Michael Kalos
Researcher at University of Pennsylvania
Publications - 105
Citations - 22490
Michael Kalos is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: T cell & Chimeric antigen receptor. The author has an hindex of 48, co-authored 104 publications receiving 19828 citations. Previous affiliations of Michael Kalos include Eli Lilly and Company & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
TL;DR: A low dose of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission.
Journal ArticleDOI
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
Stephan A. Grupp,Michael Kalos,David M. Barrett,Richard Aplenc,David L. Porter,Susan R. Rheingold,David T. Teachey,Anne Chew,Bernd Hauck,J. Fraser Wright,Michael C. Milone,Bruce L. Levine,Carl H. June +12 more
TL;DR: The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.
Journal ArticleDOI
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos,Bruce L. Levine,David L. Porter,Sharyn I. Katz,Stephan A. Grupp,Stephan A. Grupp,Adam Bagg,Carl H. June +7 more
TL;DR: It is reported that CAR T cells that target CD19 and contain a costimulatory domain from CD137 and the T cell receptor ζ chain have potent non–cross-resistant clinical activity after infusion in three of three patients treated with advanced chronic lymphocytic leukemia (CLL).
Journal ArticleDOI
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.
Pablo Tebas,David Stein,Winson Tang,Ian Frank,Shelley Wang,Gary Lee,S. Kaye Spratt,Richard T. Surosky,Martin Giedlin,Geoff Nichol,Michael C. Holmes,Philip D. Gregory,Dale G. Ando,Michael Kalos,Ronald G. Collman,Gwendolyn Binder-Scholl,Gabriela Plesa,Wei-Ting Hwang,Bruce L. Levine,Carl H. June +19 more
TL;DR: CCR5-modified autologous CD4 T-cell infusions are safe within the limits of this study, and HIV RNA became undetectable in one of four patients who could be evaluated.
Journal ArticleDOI
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette,Edward A. Stadtmauer,Marcela V. Maus,Aaron P. Rapoport,Bruce L. Levine,Lyndsey Emery,Leslie A. Litzky,Adam Bagg,Beatriz M. Carreno,Patrick J. Cimino,Gwendolyn Binder-Scholl,Dominic P. Smethurst,Andrew B. Gerry,Nick Pumphrey,Alan D. Bennett,Joanna E. Brewer,Joseph Dukes,Jane Harper,Helen K. Tayton-Martin,Bent K. Jakobsen,Namir J. Hassan,Michael Kalos,Carl H. June +22 more
TL;DR: Clinical testing of engineered T cells expressing an affinity-enhanced TCR against HLA-A*01-restricted MAGE-A3 demonstrated that TCR-engineered T cells can have serious and not readily predictable off-target and organ-specific toxicities and highlight the need for improved methods to define the specificity of engineeredTCRs.